Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.57 USD | +4.40% | +9.19% | +72.71% |
Sales 2024 * | 604K 50.38M | Sales 2025 * | 8.03M 670M | Capitalization | 274M 22.83B |
---|---|---|---|---|---|
Net income 2024 * | -99M -8.25B | Net income 2025 * | -93M -7.75B | EV / Sales 2024 * | 453 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 34.1 x |
P/E ratio 2024 * |
-2.74
x | P/E ratio 2025 * |
-3.5
x | Employees | 122 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals, Inc.
1 day | +4.40% | ||
1 week | +9.19% | ||
Current month | -23.85% | ||
1 month | -18.88% | ||
3 months | +71.87% | ||
6 months | +139.75% | ||
Current year | +72.71% |
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 25/19/25 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 01/02/01 |
Chief Tech/Sci/R&D Officer | - | 01/07/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 01/03/01 |
Lota Zoth
BRD | Director/Board Member | 64 | 01/18/01 |
Jay Shepard
BRD | Director/Board Member | 66 | 15/20/15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 10.57 | +4.40% | 196,113 |
25/24/25 | 10.12 | -0.34% | 154,741 |
24/24/24 | 10.16 | -2.03% | 246,812 |
23/24/23 | 10.37 | +3.49% | 242,734 |
22/24/22 | 10.02 | +3.51% | 335,745 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.71% | 274M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- INO Stock